Novartis Investigative Site
East Hanover, New Jersey, 07936-1080, United States
NCT Number: NCT07180238
This is a concept elicitation study on patient's experiences of Sepsis-associated Acute Kidney Injury (SA-AKI)
Looking for future studies?
Notify Me18 year–85 year
All sexes
Observational
East Hanover, New Jersey, 07936-1080, United States
The purpose of this study is to elicit concepts of interests in patients who experienced SA-AKI. The study also aims to map experiences from patient and caregiver perspectives, including treatment pathways and barriers to SA-AKI treatment, the burden of SA-AKI and unmet needs, and the disease's humanistic, societal, and economic impacts. This study is a cross-sectional, non-interventional qualitative interview study of up to 30 people who have experienced SA-AKI from the US and Germany. Participants will be screened for eligibility, provide consent, and complete a virtual, hybrid 60-minute semi-structured concept elicitation (CE) and patient experience interview. Transcripts will be reviewed by analysts and analysed according to a qualitative analysis plan including a thematic analysis of the coded transcripts. This is a minimal risk study. All information will be kept confidential, and information will be stored on a secure network which is only accessible to the study team.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Potential participants who were diagnosed with SA-AKI (KDIGO stage I, II or III) must meet the following eligibility criteria:
Participants will be required to present confirmation of diagnosis (COD) rather than relying on a self-reported diagnosis. Sepsis and AKI diagnoses will be confirmed through one of the following:
Potential caregiver participants must meet the following criteria:
Exclusion criteria
Potential participants are not eligible if they meet any of the following criteria:
Time frame: Up to 3 months
A 60-min qualitative interview will be conducted and transcripts will be coded to assess which signs, symptoms and impacts of SA-AKI have been experienced by the participant
Time frame: Up to 3 months
A 60-min qualitative interview will be conducted and transripts will be coded to assess the treatment pathways and barriers to SA-AKI treatment, the burden of SA-AKI and unmet needs, and the humanistic, societal, and economic impacts
Novartis Pharmaceuticals
Industry
Concept Elicitation and Patient Experience Mapping in Sepsis-associated Acute Kidney Injury
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03628300
Acute Kidney Injury, Beta Lactams
Amiens, France
View Trial DetailsNCT05900284
Acute Kidney Injury, Female Urogenital Diseases
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT06498336
Acute Kidney Injury, Acute Kidney Injury Due to Sepsis
Ostrava, Moravian-Silesian Region, Czechia
View Trial DetailsNCT05996835
Acute Kidney Injury, Acute Kidney Injury Due to Sepsis
Birmingham, Alabama, United States
View Trial Details